Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liushen pill for mild/normal and asymptomatic COVID-19 infection
ChiCTR2200058859Phase 4Not yet recruiting
- Sponsor
- Suzhou Fifth People's Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of liushenwan in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Suzhou Fifth People's Hospital. Primary endpoints: Time to lift quarantine (asymptomatic infection, mild), Length of hospital stay (general-type COVID-19) and 1 more. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
liushenwan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200058859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058859.